RELATED SOCIETY LINKS

Message sent on behalf of University of Toronto and University Health Network Division of Infection Diseases

Dear colleagues,

We invite you to participate in a brief survey exploring the use of the adjuvanted recombinant zoster vaccine (Shingrix) in patients post cellular therapies (allogeneic and autologous haematopoietic cell transplant, CAR-T cell therapy).

As vaccination strategies continue to evolve, your insights are invaluable in helping to understand current practices, identify areas of variation, and inform future guidelines.

The survey takes approximately 15 minutes to complete. All responses are anonymous and confidential and participation is entirely voluntary.

To access the survey, please click the link below

https://external.redcap.uhn.ca/surveys/?s=MKMDR8JM8XKHTMXE

Thank you for your time and contribution to this important work. We plan to keep this survey open for 6 weeks.

Sincerely,

Dr Victoria Hall

Clinician Investigator, University of Toronto and University Health Network

Division of Infection Diseases

Toronto, Ontario, Canada